Datasets:

---

idleengine

/

reddit_finance_posts_sp500

like 0

Follow

idleengine 1

ERROR: type should be string, got " \n\nhttps://preview.redd.it/ihsgilvrzw881.png?width=1543&format=png&auto=webp&s=ae0e0cea8ffab662ce84ac69a5a510ab5f03500b\n\nBioRestorative Therapies Inc (NASDAQ: BRTX) emerged from bankruptcy on 11/16/20 with the commons intact, it had its up and down in the OTC due to its debts that former CEO of 10 years took, with convertible notes at 50%-60% discount to market that led to declined price, they are all disclosed in previous fillings . Just a brief summary, New CEO, Lance Alstodt was appointed for reorganization, Mr. Alstodt brings over 25 years of experience in leading medical technology and life sciences companies in operations, capital raising activities, strategy, and mergers and acquisitions. Auctus Management lend them money to continue operating and try to start the trial and uplist where institution can invest in the company and raise funding for Phase 2 Clinical Trials. With all the warrants and debt it had during bankruptcy, there was no other choices but to do RS (definitely hurts the old OTC shareholders) but in conjunction to the RS, CEO managed to get an agreement for warrants and common shares to be locked up in certain conditions, please read fillings. It was aggressively done so, to make sure it meets its requirement in NASDAQ, because it could have been worse, another bk, but no, it met NASDAQ requirement and it was uplisted on 11/4/21. This is like a Phoenix rising from the ashes.\n\n**Can we skip to the good part!**\n\n​\n\nhttps://preview.redd.it/8tj5lqhtzw881.png?width=898&format=png&auto=webp&s=7c049a9a77e5def5c58b90d62a7e036a4688fa0b\n\nAlong the way to NASDAQ it had appointed two new independent members to its Board of Directors with industry and medical device experience: Patrick F. Williams, Chief Financial Officer at STAAR Surgical (Market Cap of 5.4B and trading at $110), and David Rosa, President and Chief Executive Officer at NeuroOne and a new CFO Robert Kristal with an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which have developed a notable presence in healthcare research and capital market activities. Most recently he served as the Head of Research for H.C. Wainwright.\n\n***INSIDERS BUYING!***\n\nhttps://preview.redd.it/o6js5vsuzw881.png?width=697&format=png&auto=webp&s=5300a729a28202661ea8aa262ee792a135faad8f\n\n​\n\n***Institutional Investors/ Hedge Funds coming in filling their 13G.***\n\nhttps://preview.redd.it/1zpnjsyvzw881.png?width=821&format=png&auto=webp&s=770a1fa17f8508bd4619c526c05b4936fb9cb8a4\n\nAltium Capital Management invested $2M into Biorestorative Therapies.\n\n​\n\nhttps://preview.redd.it/3th5szwyzw881.png?width=833&format=png&auto=webp&s=adbe5da9694ff65a1b8724d6368b42323d79fe49\n\nChecklist in the near term goals.\n\n◾️We can expect more SC 13G’s to be rolling out. (Sabby and Altium only has been filed expect more to come)\n\n◾️News of contract with a CRO. (PR out)\n\nhttps://preview.redd.it/gdska5d00x881.png?width=805&format=png&auto=webp&s=9686bc99d7fe93c4af305221ac7e1f9098db9245\n\n◾️News of pre-clinical animal study for metabolic program.\n\n◾️Issuance of new patents relating to metabolic program.\n\n◾️News of product manufacturing clearance.\n\n◾️News of established clinical sites for BRTX-100 clinical trial.\n\n(OTC)BRTXQ->BRTXD->(NASDAQ)-BRTX\n\nhttps://preview.redd.it/39okxqx10x881.png?width=812&format=png&auto=webp&s=26dd3a66f6294feec78ad827e9c9ebdd2e057ade\n\nhttps://preview.redd.it/esfswke30x881.png?width=835&format=png&auto=webp&s=9a55cd690dd5a4811df18dec1625f37e6057c858\n\n​\n\n***BRTX-100 stem cell product ready for P-2, Used successfully in Cayman Islands (FDA approval not required). Regenexx licenses IP to BRTX who licenses the complete procedure back to Rgnx and sold as Regenexx-C Intradiscal.***\n\n[***Regenexx-C Intradiscal — Regenexx Cayman Orthopedic***](https://regenexxcayman.com/treatments/regenexx-c-intradiscal/)\n\n***Some heavy hitters have gone there for treatment ... well known Dr. Josh Axe and many pro athletes have used Regenexx-C/Intradiscal for joints throughout body, same procedure (BRTX seeking disc approval)*** [***https://regenexxcayman.com/patient-testimonials/***](https://regenexxcayman.com/patient-testimonials/)\n\n***The science is sound, and is already used everyday to improve lives, just at $20G+ a pop, not insurance covered and not in US yet. FDA approval would change that.***\n\n***Imagine all the locations BRTX100 can reach once all trials are done and FDA approval. Below is the location of*** [***Regenexx***](https://regenexx.com/#gref)***. Essentially BRTX distribution network is being established. Not advice, still risks, do your own due diligence.***\n\nhttps://preview.redd.it/ewjorki50x881.png?width=824&format=png&auto=webp&s=cdf9ba19345583a507089d60e056c47b7c802fd9\n\nhttps://preview.redd.it/i5yhe9r50x881.png?width=743&format=png&auto=webp&s=7838a946f72c6a2e4af714ac7aa73a98d0772936\n\n​\n\n**Biorestorative have studies that show** [**normoxic vs hypoxic cells**](https://pubmed.ncbi.nlm.nih.gov/30097061/) **for their product BRTX100. 50% cell death in normoxic.** [**$BRTX**](https://twitter.com/search?q=%24BRTX&src=cashtag_click) **enter 40mm cells.** [**$MESO**](https://twitter.com/search?q=%24MESO&src=cashtag_click) **Mesoblast can only do 6mm cells. Strong patient preference for ones own cell vs cadaver. No animal products in BRTX. BRTX use platelet lysate, they use H acid. Lysate also has certain nutrients to help cell survival and structure.**\n\nhttps://preview.redd.it/s7ogzl070x881.png?width=794&format=png&auto=webp&s=892ac68330cfc2acece4876389c388105a27fcf0\n\n​\n\nMesoblast Market cap is $800M just European market, BioRestorative is in a early stage biotech company and has a lot of room to grow, US Market.\n\nhttps://preview.redd.it/qhdvi9980x881.png?width=756&format=png&auto=webp&s=99151373d67d43b9720beabab61d3b59de743252\n\n​\n\n[**https://www.biopharma-reporter.com/Article/2019/09/12/Gruenenthal-partners-with-Mesoblast-for-back-pain-cell-therapy**](https://www.biopharma-reporter.com/Article/2019/09/12/Gruenenthal-partners-with-Mesoblast-for-back-pain-cell-therapy)\n\n**Recently downgraded partnership deal after Phase 3 initial results not achieving its primary outcome measure between the treatment groups.**\n\n**With BRTX having more advantage in using hypoxic MSCs and patients own cells, BioRestorative stands a shot. #DoTheMath**\n\n[**https://pubmed.ncbi.nlm.nih.gov/30097061/**](https://pubmed.ncbi.nlm.nih.gov/30097061/)\n\n**Low float company! Fully Funded for Phase 2 and Trials starting!**\n\nhttps://preview.redd.it/rxmhith90x881.png?width=732&format=png&auto=webp&s=90e6271c18de199cbb9ace1c26c60348194c7982\n\nhttps://preview.redd.it/vvzhvi4a0x881.png?width=760&format=png&auto=webp&s=bf2af997a6a523709d80afa66d60a64e6a3c687d\n\n​\n\n**About BioRestorative Therapies, Inc.**\n\n**BioRestorative Therapies, Inc. (**[**www.biorestorative.com**](https://www.globenewswire.com/Tracker?data=G48NSWPkqD7gz0u-ebI2FYhb6wUgyzK9uJKtKuKhBmxTeXfR_EMNKom_6SGqDjoQk-P1KqzSaWdopkmHPRPveSa0XJMwWVDxBG9QpHa6fVI=)**) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:**\n\n**• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate,** ***BRTX-100,*** **is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The** ***BRTX-100*** **production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure,** ***BRTX-100*** **is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using** ***BRTX-100*** **to treat chronic lower back pain arising from degenerative disc disease.**\n\n**• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.**\n\n**BRTX Thermostem IP is protected international. The market target for their metabolic program is huge. Also if its worth noting they have done research collaboration with Pfizer before look it up.**\n\n​\n\nhttps://preview.redd.it/0dhju2ib0x881.png?width=882&format=png&auto=webp&s=be56ef80a6d55eaae650133e6a06ee2ec3702dbf\n\nhttps://preview.redd.it/5xkodv7c0x881.png?width=764&format=png&auto=webp&s=2a1febeb5f66437f4afcbf39c46288e0d2556d3c\n\n**(OTC)BRTXQ->BRTXD->(NASDAQ)-BRTX**\n\nhttps://preview.redd.it/ghkva25d0x881.png?width=631&format=png&auto=webp&s=e054638a737fa15fba12a143e629fe9489b112fa\n\n​\n\n[**https://spine-device.medicaltechoutlook.com/vendors/top-spine-device-companies-rid-156.html**](https://spine-device.medicaltechoutlook.com/vendors/top-spine-device-companies-rid-156.html)\n\n**Sec Report-** [**https://sec.report/CIK/0001505497/1#documents**](https://sec.report/CIK/0001505497/1#documents)\n\n**Public Presentation -**[**https://www.biorestorative.com/ir/wp-content/uploads/2021/06/BRTX-EG-Investor-Presentation-Final.pdf**](https://www.biorestorative.com/ir/wp-content/uploads/2021/06/BRTX-EG-Investor-Presentation-Final.pdf)\n\n**Emerging Growth with BioRestorative Therapies-** [**https://www.youtube.com/watch?v=HfQ8R0oAh7M**](https://www.youtube.com/watch?v=HfQ8R0oAh7M) **-**\n\n[**Twitter DD Thread**](https://twitter.com/TheWolfOfOTC/status/1361448224654000135?s=20)\n\n**Some back stories to be aware of brtx has some multiple bear basher but this basher stands out the most. The company wouldn't have been stronger as common would have been wiped out if it went to the hands of the IP attorney.**\n\nhttps://preview.redd.it/wq5mg88e0x881.png?width=924&format=png&auto=webp&s=37a0d59f51f103a2373ca6039a6e1c2f2b372b51\n\nhttps://preview.redd.it/rgba18we0x881.png?width=526&format=png&auto=webp&s=f2b4b9af31ba4fb8bcf24a1ef6af8a3afaf58ebc\n\n​\n\n***Full Disclosure:*** Nothing on this post should ever be considered to be \\*advice\\*, research, or an invitation to buy or sell any securities or *investment* product. *I do not* provide personal investment advice and I am not a qualified licensed investment advisor. All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies. *I will not* and cannot be held liable for any actions you take as a result of anything you read here. \\*\\*Conduct your own due diligence\\*\\*, or consult a licensed financial advisor or broker before making any and all investment decisions."

ERROR: type should be string, got "https://preview.redd.it/kgbqaxty00181.png?width=1543&format=png&auto=webp&s=ebde7e6d6b71960342fdccdd07147740d932fc4e\n\nBioRestorative Therapies Inc (NASDAQ: BRTX) emerged from bankruptcy on 11/16/20 with the commons intact, it had its up and down in the OTC due to its debts that former CEO of 10 years took, with convertible notes at 50%-60% discount to market that led to declined price, they are all disclosed in previous fillings . Just a brief summary, New CEO, Lance Alstodt was appointed for reorganization, Mr. Alstodt brings over 25 years of experience in leading medical technology and life sciences companies in operations, capital raising activities, strategy, and mergers and acquisitions. Auctus Management lend them money to continue operating and try to start the trial and uplist where institution can invest in the company and raise funding for Phase 2 Clinical Trials. With all the warrants and debt it had during bankruptcy, there was no other choices but to do RS (definitely hurts the old OTC shareholders) but in conjunction to the RS, CEO managed to get an agreement for warrants and common shares to be locked up in certain conditions, please read fillings. It was aggressively done so, to make sure it meets its requirement in NASDAQ, because it could have been worse, another bk, but no, it met NASDAQ requirement and it was uplisted on 11/4/21. This is like a Phoenix rising from the ashes.\n\nCan we skip to the good part!\n\n​\n\nhttps://preview.redd.it/zpi4axtg00181.png?width=898&format=png&auto=webp&s=08f23b7fc518e00b14da59c8162b56de759f45d7\n\nAlong the way to NASDAQ it had appointed two new independent members to its Board of Directors with industry and medical device experience: Patrick F. Williams, Chief Financial Officer at STAAR Surgical (Market Cap of 5.4B and trading at $110), and David Rosa, President and Chief Executive Officer at NeuroOne and a new CFO Robert Kristal with an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which have developed a notable presence in healthcare research and capital market activities. Most recently he served as the Head of Research for H.C. Wainwright.\n\n***INSIDERS BUYING!***\n\nhttps://preview.redd.it/czjf8w8b00181.png?width=697&format=png&auto=webp&s=79a1b2f3d76c87439a986aabd92896a4994061c9\n\n***Institutional Investors/ Hedge Funds coming in filling their 13G.***\n\nhttps://preview.redd.it/lkswzb2400181.png?width=821&format=png&auto=webp&s=cb7eeb3085c2523e461ac7f6a53c8009e089e43d\n\nAltium Capital Management invested $2M into Biorestorative Therapies.\n\n​\n\nhttps://preview.redd.it/cg9m4m1yzz081.png?width=833&format=png&auto=webp&s=e7d81b4fb50b7123d0a5e1b10d4c48a082c585b9\n\nChecklist in the near term goals.\n\n◾️We can expect more SC 13G’s to be rolling out. (Sabby and Altium only has been filed expect more to come)\n\n◾️News of contract with a CRO. (PR out)\n\n​\n\nhttps://preview.redd.it/o7lygcrrzz081.png?width=805&format=png&auto=webp&s=a33a6246688def7fea8839edbe0584acbd316ba7\n\n◾️News of pre-clinical animal study for metabolic program.\n\n◾️Issuance of new patents relating to metabolic program.\n\n◾️News of product manufacturing clearance.\n\n◾️News of established clinical sites for BRTX-100 clinical trial.\n\n(OTC)BRTXQ->BRTXD->(NASDAQ)-BRTX\n\nhttps://preview.redd.it/01yra5nnzz081.png?width=812&format=png&auto=webp&s=54991a0bdd6853f6787fff64a01ca37481cca487\n\nhttps://preview.redd.it/j1dngyekzz081.png?width=835&format=png&auto=webp&s=c2e177ea25e1bfe5f9b7d1d7282079409110de93\n\n​\n\nBRTX-100 stem cell product ready for P-2, Used successfully in Cayman Islands (FDA approval not required). Regenexx licenses IP to BRTX who licenses the complete procedure back to Rgnx and sold as Regenexx-C Intradiscal.\n\n[Regenexx-C Intradiscal — Regenexx Cayman Orthopedic](https://regenexxcayman.com/treatments/regenexx-c-intradiscal/)\n\nSome heavy hitters have gone there for treatment ... well known Dr. Josh Axe and many pro athletes have used Regenexx-C/Intradiscal for joints throughout body, same procedure (BRTX seeking disc approval) [https://regenexxcayman.com/patient-testimonials/](https://regenexxcayman.com/patient-testimonials/)\n\nThe science is sound, and is already used everyday to improve lives, just at $20G+ a pop, not insurance covered and not in US yet. FDA approval would change that.\n\nImagine all the locations BRTX100 can reach once all trials are done and FDA approval. Below is the location of [Regenexx](https://regenexx.com/#gref). Essentially BRTX distribution network is being established. Not advice, still risks, do your own due diligence.\n\n​\n\nhttps://preview.redd.it/izlrrwtgzz081.png?width=824&format=png&auto=webp&s=52d065e743a7694b67701fe2097b6f72ec9a5760\n\nhttps://preview.redd.it/eqhldkedzz081.png?width=743&format=png&auto=webp&s=fe7f9dbf225033b9f922a4580d32e3fce1930dbf\n\nBiorestorative have studies that show [normoxic vs hypoxic cells](https://pubmed.ncbi.nlm.nih.gov/30097061/) for their product BRTX100. 50% cell death in normoxic. [$BRTX](https://twitter.com/search?q=%24BRTX&src=cashtag_click) enter 40mm cells. [$MESO](https://twitter.com/search?q=%24MESO&src=cashtag_click) Mesoblast can only do 6mm cells. Strong patient preference for ones own cell vs cadaver. No animal products in BRTX. BRTX use platelet lysate, they use H acid. Lysate also has certain nutrients to help cell survival and structure.\n\n​\n\nhttps://preview.redd.it/2dvd4yp7zz081.png?width=794&format=png&auto=webp&s=7cc4254ced1e47f788e4b21e7d7d90032e5c4789\n\nMesoblast Market cap is $800M just European market, BioRestorative is in a early stage biotech company and has a lot of room to grow, US Market.\n\n​\n\nhttps://preview.redd.it/5igmcfw1zz081.png?width=756&format=png&auto=webp&s=92844125b5b54d6ad8dcd4372cebbfff6a713645\n\n[https://www.biopharma-reporter.com/Article/2019/09/12/Gruenenthal-partners-with-Mesoblast-for-back-pain-cell-therapy](https://www.biopharma-reporter.com/Article/2019/09/12/Gruenenthal-partners-with-Mesoblast-for-back-pain-cell-therapy)\n\nRecently downgraded partnership deal after Phase 3 initial results not achieving its primary outcome measure between the treatment groups.\n\nWith BRTX having more advantage in using hypoxic MSCs and patients own cells, BioRestorative stands a shot. #DoTheMath\n\n​\n\nhttps://preview.redd.it/hvmljwuvyz081.png?width=732&format=png&auto=webp&s=c8028adfcc72d06e8c75d5a2bfbf8522110587d7\n\n[https://pubmed.ncbi.nlm.nih.gov/30097061/](https://pubmed.ncbi.nlm.nih.gov/30097061/)\n\nLow float company! Fully Funded for Phase 2 and Trials starting!\n\n​\n\nhttps://preview.redd.it/mxrcbflryz081.png?width=760&format=png&auto=webp&s=70b5549e7adbdad1da5b5f5f3346cdf422d22a26\n\nAbout BioRestorative Therapies, Inc.\n\nBioRestorative Therapies, Inc. ([www.biorestorative.com](https://www.globenewswire.com/Tracker?data=G48NSWPkqD7gz0u-ebI2FYhb6wUgyzK9uJKtKuKhBmxTeXfR_EMNKom_6SGqDjoQk-P1KqzSaWdopkmHPRPveSa0XJMwWVDxBG9QpHa6fVI=)) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:\n\n• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, *BRTX-100,* is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The *BRTX-100* production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, *BRTX-100* is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using *BRTX-100* to treat chronic lower back pain arising from degenerative disc disease.\n\n• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.\n\nBRTX Thermostem IP is protected international. The market target for their metabolic program is huge. Also if its worth noting they have done research collaboration with Pfizer before look it up. \n\n​\n\nhttps://preview.redd.it/ejqwiw8vu6181.png?width=882&format=png&auto=webp&s=d125b7f3999cb5e2bbdf9b276b3ac46ed9074655\n\nhttps://preview.redd.it/ic8q30wpwz081.png?width=764&format=png&auto=webp&s=3513261e574556ce33bc36e7adde1610366f9f98\n\n(OTC)BRTXQ->BRTXD->(NASDAQ)-BRTX\n\n​\n\nhttps://preview.redd.it/rda8sf1nxz081.png?width=631&format=png&auto=webp&s=263c95ee307c314742f4d008e3d4aaf0fd3ac60e\n\n[https://spine-device.medicaltechoutlook.com/vendors/top-spine-device-companies-rid-156.html](https://spine-device.medicaltechoutlook.com/vendors/top-spine-device-companies-rid-156.html)\n\nSec Report- [https://sec.report/CIK/0001505497/1#documents](https://sec.report/CIK/0001505497/1#documents)\n\nPublic Presentation -[https://www.biorestorative.com/ir/wp-content/uploads/2021/06/BRTX-EG-Investor-Presentation-Final.pdf](https://www.biorestorative.com/ir/wp-content/uploads/2021/06/BRTX-EG-Investor-Presentation-Final.pdf)\n\nEmerging Growth with BioRestorative Therapies- [https://www.youtube.com/watch?v=HfQ8R0oAh7M](https://www.youtube.com/watch?v=HfQ8R0oAh7M) \\-\n\n[Twitter DD Thread](https://twitter.com/TheWolfOfOTC/status/1361448224654000135?s=20)\n\nSome back stories to be aware of brtx has some multiple bear basher but this basher stands out the most. The company wouldn't have been stronger as common would have been wiped out if it went to the hands of the IP attorney.\n\n​\n\nhttps://preview.redd.it/4n3elplexz081.png?width=924&format=png&auto=webp&s=53c307e4ce136e038bd8f1b0f5ff7cdd77ddc1af\n\nhttps://preview.redd.it/17qvvhgjxz081.png?width=526&format=png&auto=webp&s=05a428a35f8f8093e04b814e6b825d2424a7cbb3\n\n***Full Disclosure:*** Nothing on this post should ever be considered to be \\*advice\\*, research, or an invitation to buy or sell any securities or *investment* product. *I do not* provide personal investment advice and I am not a qualified licensed investment advisor. All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies. *I will not* and cannot be held liable for any actions you take as a result of anything you read here. \\*\\*Conduct your own due diligence\\*\\*, or consult a licensed financial advisor or broker before making any and all investment decisions."